FindTrial
Sign In

XmAb20717

DRUG4 trials

Sponsors

Xencor, Inc., Abramson Cancer Center at Penn Medicine, M.D. Anderson Cancer Center

Conditions

Basal Cell CarcinomaBiliary Tract CancerBreast CarcinomaCastration-Resistant Prostate CarcinomaCervical CancerCervical CarcinomaCholangiocarcinomaColon Cancer

Phase 1

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
CompletedNCT03517488
Xencor, Inc.Basal Cell Carcinoma, Breast Carcinoma, Castration-Resistant Prostate Carcinoma +25
Start: 2018-07-10End: 2022-09-06Updated: 2022-12-01

Phase 2

XmAb20717 in Advanced Biliary Tract Cancers
Active, not recruitingNCT05297903
Abramson Cancer Center at Penn MedicineBiliary Tract Cancer
Start: 2022-04-11End: 2026-12-02Target: 27Updated: 2025-09-15
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
SuspendedNCT05337735
M.D. Anderson Cancer CenterCervical Carcinoma, Extrapulmonary High Grade, Hodgkin's Lymphoma +5
Start: 2022-08-05End: 2026-12-30Target: 140Updated: 2026-05-04
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
WithdrawnNCT05900648
M.D. Anderson Cancer CenterColon Cancer, Colorectal Cancer, Rectum Cancer
Start: 2023-05-17End: 2024-02-09Updated: 2024-04-29

Related Papers

Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
Journal of Clinical Oncology2023-06-014 citations
523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts2021-11-0118 citations
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts2020-11-018 citations
Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors.
Journal of Clinical Oncology2020-05-208 citations